Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
Nanodevices for the brain could thwart formation of Alzheimer's plaques
01:08pm, Thursday, 30'th Apr 2020
Alzheimer's disease is the sixth leading cause of death in the United States, affecting one in 10 people over the age of 65. Scientists are engineering nanodevices to disrupt processes in the brain th
Athenex (ATNX) Receives a Buy from Oppenheimer
02:24am, Thursday, 30'th Apr 2020
In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX), with a price target of $23.00. The company's
Athenex (ATNX) Receives a Buy from Oppenheimer
02:24am, Thursday, 30'th Apr 2020
In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX – Research Report), with
Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio
12:00pm, Tuesday, 28'th Apr 2020
SOUTH SAN FRANCISCO, Calif., April 28, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for.
Analysts Offer Insights on Healthcare Companies: Interpace Diagnostics Group (IDXG) and Principia Biopharma (PRNB)
02:22pm, Thursday, 23'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Interpace Diagnostics Group (IDXG) and Principia Biopharma
Oppenheimer Keeps Their Buy Rating on Athenex (ATNX)
09:57pm, Wednesday, 22'nd Apr 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX), with a price target of $23.00. The company's shares
Oppenheimer Keeps Their Buy Rating on Athenex (ATNX)
09:57pm, Wednesday, 22'nd Apr 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX – Research Report), with
Exact Sciences (EXAS) Gets a Buy Rating from Oppenheimer
12:31am, Wednesday, 22'nd Apr 2020
In a report released yesterday, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Exact Sciences (EXAS), with a price target of $115.00. The
Exact Sciences (EXAS) Gets a Buy Rating from Oppenheimer
12:31am, Wednesday, 22'nd Apr 2020
In a report released yesterday,
Kevin DeGeeter
from Oppenheimer assigned a
Buy
rating to Exact Sciences (
EXAS
–
Research Report
), with a price target of
$115.00
. The company’s shares closed las
Top Ranked Momentum Stocks to Buy for April 21st
02:53pm, Tuesday, 21'st Apr 2020
Top Ranked Momentum Stocks to Buy for April 21st
Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)
12:00pm, Tuesday, 21'st Apr 2020
“We are pleased to have successfully completed the DalcA Phase 2b trial during this challenging pandemic and remain on track to report final results later this quarter,” said Nassim Usman, Ph.D.,
Analysts Are Bullish on These Healthcare Stocks: Eagle Pharmaceuticals (EGRX), Actinium Pharmaceuticals (ATNM)
02:27pm, Friday, 17'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Actinium Pharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: Eagle Pharmaceuticals (EGRX), Actinium Pharmaceuticals (ATNM)
02:27pm, Friday, 17'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals
Dublin, April 17, 2020 -- The "Impact of COVID-19 on Global Digital PCR Industry" report has been added to ResearchAndMarkets.com's offering. Global Digital.
